Alnylam Is Now The Leader In The Clinical HBV RNAi Therapy Space
November 30, 2016 at 09:32 AM EST
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced the discontinuation of all its clinical RNAi programs, citing safety issues. ...